TrialThe oncologist2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma.

Nguyen H Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.